Company intelligence / Profile preview

Shouyao Holdings

Ownership: Private
Employees: ~178
Development stage: Commercial

Overview

Shouyao Holdings is a publicly traded Chinese biotech company focused on the research and development of innovative small molecule drugs, primarily targeting oncology and metabolic diseases. Its lead programs include ALK inhibitors and other targeted therapies in late-stage clinical trials for various cancers including non-small cell lung cancer, lymphoma, hepatocellular carcinoma, as well as type II diabetes[2][6]. The company has multiple assets in clinical development with at least one program reaching Phase 3 trials[6].

Therapeutic areas: OncologyEndocrinology
Modalities: Small moleculeProteolysis-targeting chimera therapy
Industry: Biotech

Drug pipeline

12 assets

ficonalkib

11 more assets in the full pipeline.

Request access →

Partnerships

PharmaBlock Sciences

Beyond the preview

Go deeper on Shouyao Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shouyao Holdings.

Explore the full profile